INDP
Indaptus Therapeutics, Inc.
Healthcare — Biotechnology
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Price History
Fundamentals
| Market Cap | $391.73M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.12 |
| EPS (TTM) | $-12.70 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -931.79% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 56.3 |
| Beta | 1.27 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $13.40 |
| 52-Week Low | $0.92 |
| 50-Day Avg | $2.59 |
| 200-Day Avg | $2.53 |
| Avg Volume | $1.03M |
| Volume | 50.8K |
Performance Analysis
NEUTRALINDP presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:15 UTC
Back to Screener Export Report